Drug intelligence / Profile preview

OSU-6162

Development stage: Phase 2
Lead developer: NeuroSearch
Modality: Small Molecules
Administration: Oral

Overview

OSU-6162 is an investigational small molecule drug that acts as a dual dopaminergic and serotonergic stabilizer. It is primarily used to modulate dopamine D2 and serotonin 5-HT2A receptors, functioning as a partial agonist or antagonist depending on the context. It is being studied for its potential in treating various neurological conditions, including bipolar depression, treatment-resistant depression, chronic fatigue syndrome, and post-stroke symptoms. The drug is developed by Carlsson Research AB and has been involved in clinical trials with other developers like Pfizer and Goteborg University.

Other names: OSU6162OSU-6162OSU 6162

Targets

SIGMAR1 (Sigma non-opioid intracellular receptor 1)DRD2 (Dopamine D2 Receptor)HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on OSU-6162.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OSU-6162.

Explore the full profile